Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Biotechnology

Healthcare
$3.77 -3.37%

-$0.34 today

Market cap
$186.36M
Beta
2.40
P/E (TTM)
-2.7
EPS (TTM)
-$3.53
52W Low $1.47High $14.53

Volume 0.97M

Average 0.48M

ARTV Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

Artiva Biotherapeutics, Inc.NASDAQ: ARTV

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses declines year over year

Q1 FY2026 other income / expenses of $914K fell 50.9% year over year, in line with the -50.6% change in trailing-twelve-month other income / expenses. Sequentially, it fell 21.2% from the prior quarter. Over 3 fiscal years it compounded at +65.3% a year.

Context

  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -50.9% toward the trailing-twelve-month pace of -50.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$914K-21.2% QoQ
Last fiscal yearDec 2025
$6.75M-23.3% YoY
LTMMar 2026
$5M-50.6% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.9%——
1 year-23.3%——
3-year CAGR+65.3%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
6.75M USD
Year-over-year change
-23.3%

Other Income / Expenses vs competitors

How ARTV compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -50.6% is the 3rd highest of 9, against a peer median of -84.5%.
  • Over three fiscal years its annual growth of +65.3% compares with a peer median of +10.5%.
ARTV Competitors
Other Income / Expenses for ARTV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$21.47M USD+277.4%——
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$5M USD-50.6%+65.3%—
CNTBConnect Biopharma Holdings LimitedFY2025$2.79M USD-60.4%+22.4%4360.9%
STTKShattuck Labs, Inc.LTM Mar 2026$2.79M USD-35.2%+24.9%279.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$2.3M USD-64.6%-16.7%—
IFRXInflaRx N.V.LTM Mar 2026-€440.14K EUR-104.4%-1.4%1500.6%
DTILPrecision BioSciences, Inc.LTM Mar 2026-$5.37M USD-124.3%—11.9%
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$15.12M USD-297.9%——
STROSutro Biopharma, Inc.LTM Mar 2026-$38.64M USD-613.7%—38.8%
Peer median (excluding ARTV) —-84.5%+10.5%279.0%

Competitors are the stored peer set for ARTV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2M4.93M33.49M251K0
Cost of Revenue00002.6M
Gross Profit2M4.93M33.49M251K(2.6M)
Gross Margin100.0%100.0%100.0%100.0%—
Research & Development42.41M43.98M50.25M50.33M69.54M
Selling, General & Admin12.86M20.78M13.91M17.21M20.27M
Operating Expenses55.27M64.76M64.16M67.53M88.01M
Depreciation & Amortization248K1.16M2.27M2.43M2.6M
EBITDA(71.58M)(57.18M)(25.36M)(56.06M)(81.27M)
EBITDA Margin-3575.3%-1159.5%-75.7%-22335.5%—
Operating Income(53.27M)(59.83M)(30.67M)(67.28M)(90.61M)
Operating Margin-2660.9%-1213.3%-91.6%-26805.6%—
Interest Income01.29M2.54M5.35M5.96M
Interest Expense00000
Other Income / Expenses(18.55M)1.49M3.05M8.79M6.75M
Income Before Tax(71.83M)(58.34M)(27.62M)(58.49M)(83.87M)
Pre-Tax Margin-3587.7%-1183.0%-82.5%-23304.0%—
Income Tax Expense053K72K00
Net Income(71.83M)(58.39M)(27.7M)(58.49M)(83.87M)
Net Margin-3587.7%-1184.1%-82.7%-23304.0%—
EPS (Basic)(4.08)(3.32)(1.19)(5.20)(3.43)
EPS (Diluted)(4.08)(3.32)(1.19)(5.20)(3.43)
Weighted Avg Shares17.58M17.58M23.28M24.36M24.44M
Weighted Avg Shares (Diluted)17.58M17.58M23.28M24.36M24.44M

Artiva Biotherapeutics, Inc.

NASDAQ:ARTV

Intrinsic Alpha fair value

Locked

Current Price

$3.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.